2nd Quarter - Report

MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY for MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY

Firm
Client
Income
—
Expenses
$460,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).

LobbyistCovered position, as disclosed
JOSHUA C BABB —
BRIAN BRANTON Chief of Staff, Congressman Polis; Chief of Staff, Congressman Sestak; Legislative Director, Congressman Wu; Legislative Counsel, Congressman Holt; Legislative Assistant, Congresswoman Mink
RICHARD BUCKLEY —
JASEY CARDENAS —
DIANA FELNER —
BEN JONES —
JOHN RICHARDSON New —
MATTHEW WILLIAMS —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; White House Office

Bills named: H.R. 3521 (119th), H.R. 1 (119th)

Medicare/Medicaid MMM

H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; Inflation Reduction Act (IRA) reform on drug pricing and add on fee (Protecting Patient Access to Cancer and Complex Therapies Act (not reintroduced in 119th)) (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency

LobbyistCovered position, as disclosed
JASEY CARDENAS —
BEN JONES —
JOHN RICHARDSON New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: H.R. 2120 (119th), S. 1816 (119th), H.R. 2484 (119th), H.R. 3514 (119th), H.R. 879 (119th)

Pharmacy PHA

H.R. 3164, Ensuring Community Access to Pharmacist Services Act

LobbyistCovered position, as disclosed
JOSHUA C BABB —
BRIAN BRANTON Chief of Staff, Congressman Polis; Chief of Staff, Congressman Sestak; Legislative Director, Congressman Wu; Legislative Counsel, Congressman Holt; Legislative Assistant, Congresswoman Mink
RICHARD BUCKLEY —
DIANA FELNER —
MATTHEW WILLIAMS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 3164 (119th)

Manufacturing MAN

H.R. 2444, Promoting Resilient Supply Chains Act; S. 257, Promoting Resilient Supply Chains

LobbyistCovered position, as disclosed
JOSHUA C BABB —
BRIAN BRANTON Chief of Staff, Congressman Polis; Chief of Staff, Congressman Sestak; Legislative Director, Congressman Wu; Legislative Counsel, Congressman Holt; Legislative Assistant, Congresswoman Mink
RICHARD BUCKLEY —
DIANA FELNER —
MATTHEW WILLIAMS —

Contacted: Health & Human Services, Dept of (HHS); White House Office

Bills named: S. 257 (119th), H.R. 2444 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.